Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC decreased its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 3.0% during the 4th quarter, Holdings Channel reports. The firm owned 48,929 shares of the biopharmaceutical company’s stock after selling 1,494 shares during the quarter. Yousif Capital Management LLC’s holdings in Cytokinetics were worth $4,085,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Cytokinetics by 4.6% in the third quarter. Vanguard Group Inc. now owns 10,743,324 shares of the biopharmaceutical company’s stock valued at $316,498,000 after purchasing an additional 472,595 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Cytokinetics in the fourth quarter valued at $46,308,000. Rhumbline Advisers grew its holdings in Cytokinetics by 1.1% in the third quarter. Rhumbline Advisers now owns 274,869 shares of the biopharmaceutical company’s stock valued at $8,098,000 after purchasing an additional 3,005 shares during the last quarter. Rafferty Asset Management LLC boosted its stake in shares of Cytokinetics by 10.0% during the third quarter. Rafferty Asset Management LLC now owns 246,922 shares of the biopharmaceutical company’s stock valued at $7,274,000 after acquiring an additional 22,498 shares during the last quarter. Finally, Affinity Asset Advisors LLC lifted its position in Cytokinetics by 84.1% during the third quarter. Affinity Asset Advisors LLC now owns 230,366 shares of the biopharmaceutical company’s stock worth $6,787,000 after buying an additional 105,218 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on CYTK shares. StockNews.com downgraded Cytokinetics from a “hold” rating to a “sell” rating in a report on Friday, January 5th. Truist Financial restated a “buy” rating and issued a $86.00 price objective on shares of Cytokinetics in a report on Monday, April 8th. Oppenheimer restated an “outperform” rating and issued a $107.00 price objective on shares of Cytokinetics in a report on Monday, March 4th. UBS Group downgraded Cytokinetics from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $61.00 to $92.00 in a report on Wednesday, January 24th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $90.00 price objective (up from $60.00) on shares of Cytokinetics in a report on Friday, January 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $79.33.

Cytokinetics Trading Up 0.8 %

Shares of NASDAQ:CYTK opened at $65.34 on Friday. Cytokinetics, Incorporated has a one year low of $25.98 and a one year high of $110.25. The business’s 50-day simple moving average is $69.91 and its 200 day simple moving average is $59.82.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.35). The business had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $7.62 million. During the same period in the previous year, the business posted ($1.45) EPS. The firm’s quarterly revenue was down 10.5% compared to the same quarter last year. On average, analysts expect that Cytokinetics, Incorporated will post -4.5 earnings per share for the current year.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, Director John T. Henderson sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $76.48, for a total transaction of $382,400.00. Following the completion of the sale, the director now owns 42,632 shares in the company, valued at approximately $3,260,495.36. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, EVP Fady Ibraham Malik sold 32,605 shares of Cytokinetics stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $79.30, for a total value of $2,585,576.50. Following the completion of the transaction, the executive vice president now owns 142,973 shares in the company, valued at approximately $11,337,758.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director John T. Henderson sold 5,000 shares of Cytokinetics stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $76.48, for a total value of $382,400.00. Following the completion of the transaction, the director now owns 42,632 shares of the company’s stock, valued at approximately $3,260,495.36. The disclosure for this sale can be found here. Insiders sold a total of 125,876 shares of company stock worth $9,269,877 in the last 90 days. 3.40% of the stock is owned by corporate insiders.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.